Seraphina Therapeutics, based in San Diego, has recently gained scientific recognition for uncovering an emerging nutritional deficiency syndrome linked to C15:0. The discovery, made during efforts to enhance the health of aging Navy dolphins, showcases the importance of addressing this condition. The findings were announced on April 28, 2026, shedding light on the significance of this breakthrough in the field of nutrition and health.